// App-Quantinova.ai

: A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)

Researchers

Presenter

  • Yael C Cohen

Principal Investigators

  • Tamir Shragai

  • Noa Lavi

  • Iuliana Vaxman

  • Evgeni Chubar

  • Moshe E Gatt

  • Chezi Ganzel

  • Hila Magen

  • Efrat Luttwak

  • Noa Lowenton-Spier

  • Liron Gez-Aaronson

  • Natan Melamed

  • Irit Avivi

Medical Centers

  • Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

  • Division of Hematology, Tel Aviv University, Tel Aviv, Israel

  • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

  • Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel

  • Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University, Jerusalem, Israel

  • Shaare Zedek Medical Center, Jerusalem, Israel

  • Dpartment of Hematology, HaEmek Medical Center, Afula, Israel

  • Tel Aviv Sourasky (Ichilov) Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

  • Rambam Medical Center, Haifa, Israel

  • Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

  • Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Ramat-Gan, Israel

Locations

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Ixazomib

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Open Label

  • Single Arm

  • Multicenteric

  • Tolerability

  • Prospective

  • Investigator Initiated

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved